Pemetrexed and communicating hydrocephalus

Chang O. Son, Frank E. Mott

Research output: Contribution to journalArticle

Abstract

Background: Pemetrexed (Alimta) is widely used in combination with platinum as a first-line treatment of mesothelioma and adenocarcinoma of the lung. It is also approved for use in the maintenance setting as a single agent after patient completion of 4 to 6 cycles of a platinum-based doublet regimen for non- small cell lung cancer. With the increasing use of pemetrexed and longer durations of therapy, unexpected cumulative toxicity or other toxicities are possible. Case Report: We report a case of a patient receiving maintenance pemetrexed for advanced adenocarcinoma of the lung who developed communicating hydrocephalus. Conclusion: We are not aware of any other reports of communicating hydrocephalus in association with pemetrexed therapy. As more patients routinely receive pemetrexed as maintenance therapy, the development of toxicities or unexpected diagnoses is possible and may be a consideration in the chronic management of such patients.

Original languageEnglish (US)
Pages (from-to)292-294
Number of pages3
JournalOchsner Journal
Volume14
Issue number2
StatePublished - Jan 1 2014

Fingerprint

Pemetrexed
Hydrocephalus
Platinum
Maintenance
Mesothelioma
Proxy
Therapeutics
Non-Small Cell Lung Carcinoma

Keywords

  • Adenocarcinoma of the lung
  • Hydrocephalus
  • Pemetrexed

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Son, C. O., & Mott, F. E. (2014). Pemetrexed and communicating hydrocephalus. Ochsner Journal, 14(2), 292-294.

Pemetrexed and communicating hydrocephalus. / Son, Chang O.; Mott, Frank E.

In: Ochsner Journal, Vol. 14, No. 2, 01.01.2014, p. 292-294.

Research output: Contribution to journalArticle

Son, CO & Mott, FE 2014, 'Pemetrexed and communicating hydrocephalus', Ochsner Journal, vol. 14, no. 2, pp. 292-294.
Son CO, Mott FE. Pemetrexed and communicating hydrocephalus. Ochsner Journal. 2014 Jan 1;14(2):292-294.
Son, Chang O. ; Mott, Frank E. / Pemetrexed and communicating hydrocephalus. In: Ochsner Journal. 2014 ; Vol. 14, No. 2. pp. 292-294.
@article{c8bf649e556b48c9b1c316020dfb8bb2,
title = "Pemetrexed and communicating hydrocephalus",
abstract = "Background: Pemetrexed (Alimta) is widely used in combination with platinum as a first-line treatment of mesothelioma and adenocarcinoma of the lung. It is also approved for use in the maintenance setting as a single agent after patient completion of 4 to 6 cycles of a platinum-based doublet regimen for non- small cell lung cancer. With the increasing use of pemetrexed and longer durations of therapy, unexpected cumulative toxicity or other toxicities are possible. Case Report: We report a case of a patient receiving maintenance pemetrexed for advanced adenocarcinoma of the lung who developed communicating hydrocephalus. Conclusion: We are not aware of any other reports of communicating hydrocephalus in association with pemetrexed therapy. As more patients routinely receive pemetrexed as maintenance therapy, the development of toxicities or unexpected diagnoses is possible and may be a consideration in the chronic management of such patients.",
keywords = "Adenocarcinoma of the lung, Hydrocephalus, Pemetrexed",
author = "Son, {Chang O.} and Mott, {Frank E.}",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "14",
pages = "292--294",
journal = "Ochsner Journal",
issn = "1524-5012",
publisher = "Ochsner Clinic",
number = "2",

}

TY - JOUR

T1 - Pemetrexed and communicating hydrocephalus

AU - Son, Chang O.

AU - Mott, Frank E.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Pemetrexed (Alimta) is widely used in combination with platinum as a first-line treatment of mesothelioma and adenocarcinoma of the lung. It is also approved for use in the maintenance setting as a single agent after patient completion of 4 to 6 cycles of a platinum-based doublet regimen for non- small cell lung cancer. With the increasing use of pemetrexed and longer durations of therapy, unexpected cumulative toxicity or other toxicities are possible. Case Report: We report a case of a patient receiving maintenance pemetrexed for advanced adenocarcinoma of the lung who developed communicating hydrocephalus. Conclusion: We are not aware of any other reports of communicating hydrocephalus in association with pemetrexed therapy. As more patients routinely receive pemetrexed as maintenance therapy, the development of toxicities or unexpected diagnoses is possible and may be a consideration in the chronic management of such patients.

AB - Background: Pemetrexed (Alimta) is widely used in combination with platinum as a first-line treatment of mesothelioma and adenocarcinoma of the lung. It is also approved for use in the maintenance setting as a single agent after patient completion of 4 to 6 cycles of a platinum-based doublet regimen for non- small cell lung cancer. With the increasing use of pemetrexed and longer durations of therapy, unexpected cumulative toxicity or other toxicities are possible. Case Report: We report a case of a patient receiving maintenance pemetrexed for advanced adenocarcinoma of the lung who developed communicating hydrocephalus. Conclusion: We are not aware of any other reports of communicating hydrocephalus in association with pemetrexed therapy. As more patients routinely receive pemetrexed as maintenance therapy, the development of toxicities or unexpected diagnoses is possible and may be a consideration in the chronic management of such patients.

KW - Adenocarcinoma of the lung

KW - Hydrocephalus

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=84902076773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902076773&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84902076773

VL - 14

SP - 292

EP - 294

JO - Ochsner Journal

JF - Ochsner Journal

SN - 1524-5012

IS - 2

ER -